Gender and interindividual variability in pharmacokinetics

References

• Anderson, G.D. (2005). Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health 14:19–29.
   PubMed Web of Science ®Google Scholar
• Armstrong, S.C., Cozza, K.L. (2003). Antihistamines. Psychosomatics 44:430–434.
   PubMed Web of Science ®Google Scholar
• Ayrton, A., Morgan, P. (2001). Role of transport proteins in drug absorption, distribution, and excretion. Xenobiotica 31:469–497.
   Web of Science ®Google Scholar
• Baltes, B., Coupez, R., Giezek, H., Voss, G., Meyerhoff, C., Strolin Benedetti, M. (2001). Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam Clin Pharmacol 15:269–277.
   PubMed Web of Science ®Google Scholar
• Barr, J., Donner, A. (1995). Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. Crit Care Clin 11:827–487.
   PubMed Web of Science ®Google Scholar
• Barrenäs, F., Andersson, B., Cardell, L.O., Langston, M., Mobini, R., Perkins, A., et al. (2008). Gender differences in inflammatory proteins and pathways in seasonal allergic rhinitis. Cytokine 42:325–329.
   PubMed Web of Science ®Google Scholar
• Beierle, I., Meibohm, B., Derendorf, H. (1999). Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 37:529–547.
   PubMed Web of Science ®Google Scholar
• Benedek, I.H., Blouin, R.A., McNamara, P.J. (1984). Influence of smoking on serum protein composition and the protein binding of drugs. J Pharm Pharmacol 36:214–216.
   PubMed Web of Science ®Google Scholar
• Berg, U.B. (2006). Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transpl 21:2577–2582.
   PubMed Web of Science ®Google Scholar
• Berlanga, C., Flores-Ramos, M. (2006). Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 95:119–123.
   PubMed Web of Science ®Google Scholar
• Bigos, K.L., Pollock, B.G., Coley, K.C., Miller del, D., Marder, S.R., Aravagiri, M., et al. (2008). Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 48:157–165.
   PubMed Web of Science ®Google Scholar
• Bonhomme-Faivre, L., Devocelle, A., Saliba, F., Chatled, S., Maccario, J., Farinotti, R., et al. (2004). MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation 78:21–25.
   PubMed Web of Science ®Google Scholar
• Bracco, D., Landry, C., Dubois, M.J., Eggimann, P. (2008). Pharmacokinetic variability of extended interval tobramycin in burn patients. Burns 34:791–796.
   PubMed Web of Science ®Google Scholar
• Burstein, A.H., Reiss, W.G., Kantor, E., Anderson, G.D. (1998). Cytochrome P450 3A4 activity in premenopausal and postmenopausal women, based on 6-beta-hydroxycortisol:cortisol ratios. Pharmacotherapy 18:1271–1276.
   PubMed Web of Science ®Google Scholar
• Chao, S.T., Prather, D., Pinson, D., Coen, P., Pruitt, B., Knowles, M., et al. (1991). Effect of food on bioavailability of pseudoephedrine and brompheniramine administered from a gastrointestinal therapeutic system. J Pharm Sci 80:432–435.
   PubMed Web of Science ®Google Scholar
• Chiou, W.L., Chung, S.M., Wu, T.C. (2000). Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 17:903–905.
   PubMed Web of Science ®Google Scholar
• Chowbay, B., Cumaraswamy, S., Cheung, Y., Zhou, Q., Lee, E. (2003). Genetic polymorphisms in MDR1 and CY3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13:89–95.
   PubMedGoogle Scholar
• Ciccone, G.K., Holdcroft, A. (1999). Drugs and sex differences: a review of drugs relating to anaesthesia. Br J Anaesth 82:255–265.
   PubMed Web of Science ®Google Scholar
• Cohen, M., Panagides, J., Timmer, C.J., Huisman, J.A. (1997). Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal. Eur J Drug Metab Pharmacokinet 22:103–110.
   PubMed Web of Science ®Google Scholar
• Cvetkovic, M., Leake, B., Fromm, M.F., Wilkinson, G.R., Kim, R.B. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866–871.
   PubMed Web of Science ®Google Scholar
• Dadashzadeh, S., Javadian, B., Sadeghian, S. (2006). The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm Drug Dispos 27:329–334.
   PubMed Web of Science ®Google Scholar
• Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R.J., Mohrenweiser, H.W., et al. (2001). Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299:825–831.
   PubMed Web of Science ®Google Scholar
• Davis, M. (2005). Gender differences in P-glycoprotein: drug toxicity and response. J Clin Oncol 23:6439–6440.
   PubMed Web of Science ®Google Scholar
• Dekhuijzen, P.N., Koopmans, P.P. (2002). Pharmacokinetic profile of zafirlukast. Clin Pharmacokinet 41:105–114
   PubMed Web of Science ®Google Scholar
• DeNardo, G., Yuan, A., Goldstein, D., Richman, C., O’Donnell, R., Shen, S., et al. (2003). Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs. Cancer Biother Radiopharm 18:231–237.
   PubMed Web of Science ®Google Scholar
• Denton, T.T., Zhang, X., Cashman, J.R. (2004). Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem Pharmacol 67:751–756.
   PubMed Web of Science ®Google Scholar
• Desai, H.D., Seabolt, J., Jann, M.W. (2001). Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 15:469–494.
   PubMed Web of Science ®Google Scholar
• Doki, K., Homma, M., Kuga, K., Aonuma, K., Sakai, S., Yamaguchi, I., et al. (2007). Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol 63:951–957.
   PubMed Web of Science ®Google Scholar
• Drescher, S., Schaeffeler, E., Hitzl, M., Hofmann, U., Schwab, M., Brinkmann, U., et al. (2002). MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 53:526–534.
   PubMed Web of Science ®Google Scholar
• Dresser, G.K., Schwarz, U.I., Wilkinson, G.R., Kim, R.B., Roden, D.M. (2001). Fexofenadine bioavailability modulated by dietary salt. Clin Pharmacol Ther 69:23.
   Google Scholar
• Drici, M.D., Clément, N. (2001). Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 24:575–585.
   PubMed Web of Science ®Google Scholar
• DuBuske, L. (2007). Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol 8:271–283.
   PubMed Web of Science ®Google Scholar
• Dumez, H., Guetens, G., De Boeck, G., Highley, M.S., de Bruijn, E.A., van Oosterom, A.T., et al. (2005). In vitro partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender, and smoking. Anti-Cancer Drugs 16:893–895.
   PubMed Web of Science ®Google Scholar
• Ebert, S.N., Liu, X.K., Woosley, R.L. (1998). Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health 7:547–557.
   PubMed Web of Science ®Google Scholar
• Eiselt, R., Domanski, T.L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E., et al. (2001). Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447–458.
   PubMedGoogle Scholar
• El Desoky, E.S., Derendorf, H., Klotz, U. (2006). Variability in response to cardiovascular drugs. Curr Clin Pharmacol 1:35–46.
   PubMedGoogle Scholar
• Ernstgård, L., Sjögren, B., Warholm, M., Johanson, G. (2003). Sex differences in the toxicokinetics of inhaled solvent vapors in humans 2.2-propanol. Toxicol Appl Pharmacol 193:158–167.
   PubMed Web of Science ®Google Scholar
• Faber, K.N., Müller, M., Jansen, P.L.M. (2003). Drug transport proteins in the liver. Adv Drug Deliv Rev 55:107–124.
   PubMed Web of Science ®Google Scholar
• Feldman, M., Richardson, C.T., Walsh, J.H. (1983). Sex-related differences in gastrin release and parietal cell sensitivity to gastrin in healthy human beings. J Clin Invest 71:715–720.
   PubMed Web of Science ®Google Scholar
• Fisher, M.M., Yousef, I.M. (1973). Sex differences in the bile acid composition of human bile: studies in patients with and without gallstones. Can Med Assoc J 109:190–193.
   PubMed Web of Science ®Google Scholar
• Flexner, C. (2008). Pharmacoecology: a new name for an old science. Clin Pharmacol Ther 83:375–379.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, Center for Drug Evaluation and Research. (2002). Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies. Silver Spring, Maryland, USA: U.S. Food and Drug Administration.
   Google Scholar
• Frick, G.S., Blum, R.A., Kovacs, S.J., Vitow, C., Stewart, J.A., Kraft, W.K. (2004). Prevalence of the slow metabolizer (SM) phenotype and single-dose pharmacokinetics (PK) of desloratadine (DCL) in a population of healthy adults. Clin Pharmacol Ther 75:P9.
   Web of Science ®Google Scholar
• Fromm, M.F., Darbar, D., Dell’Orto, S., Roden, D.M. (1999). Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading. J Pharmacol Exp Ther 290:253–258.
   PubMed Web of Science ®Google Scholar
• Gandhi, M., Aweeka, F., Greenblatt, R.M., Blaschke, T.F. (2004). Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44:499–523.
   PubMed Web of Science ®Google Scholar
• Gerloff, T., Schaefer, M., Johne, A., Oselin, K., Meisel, C., Cascorbi, I., et al. (2002). MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharm 54:610–616.
   PubMed Web of Science ®Google Scholar
• Gervasini, G., Vizcaino, S., Carrillo, J.A., Caballero, M.J., Benitez, J. (2006). The effect of CYP2J2, CYP3A4, CYP3A5, and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study. Br J Clin Pharmacol 62:177–186.
   PubMed Web of Science ®Google Scholar
• Gorski, J.C., Vannaprasaht, S., Hamman, M.A., Ambrosius, W.T., Bruce, M.A., Haehner-Daniels, B., et al. (2003). The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74:275–287.
   PubMed Web of Science ®Google Scholar
• Goryachkina, K., Burbello, A., Boldueva, S., Babak, S., Bergman, U., Bertilsson, L. (2008). CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol 64:1163–1173.
   PubMed Web of Science ®Google Scholar
• Gotoh, Y., Kato, Y., Stieger, B., Meier, P.J., Sugiyama, Y. (2002). Gender difference in the Oatp1-mediated tubular reabsorption of estradiol 17-beta-D-glucuronide in rats. Am J Physiol Endocrinol Metab 282:1245–1254.
   PubMed Web of Science ®Google Scholar
• Greenblatt, D.J., Allen, M.D., Harmatz, J.S., Shader, R.I. (1980). Diazepam disposition determinants. Clin Pharmacol Ther 27:301–312.
   PubMed Web of Science ®Google Scholar
• Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.P., von Richter, O., Zundler, J., et al. (1999). The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147–153.
   PubMed Web of Science ®Google Scholar
• Groves, C.E., Suhre, W.B., Cherrington, N.J., Wright, S.H. (2006). Sex differences in the mRNA, protein, and functional expression of organic anion transporter (Oat). 1, Oat3, and organic cation transporter (Oct). 2 in rabbit renal proximal tubules. J Pharmacol Exp Ther 316:743–752.
   PubMed Web of Science ®Google Scholar
• Hägg, S., Spigset, O., Dahlqvist, R. (2001). Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169–173.
   PubMed Web of Science ®Google Scholar
• Haji-Momenian, S., Rieger, J.M., Macdonald, T.L., Brown, M.L. (2003). Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6. Bioorg Med Chem 11:5545–5554.
   PubMed Web of Science ®Google Scholar
• Hanks, G.W., Reid, C. (2005). Contribution to variability in response to opioids. Supp Care Cancer 13:145–152.
   PubMed Web of Science ®Google Scholar
• Hashizume, T., Imaoka, S., Mise, M., Terauchi, Y., Fuji, T., Miyazaki, H., et al. (2002). Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298–304.
   PubMed Web of Science ®Google Scholar
• Hilgendorf, C., Ahlin, G., Seithel, A., Artursson, P., Ungell, A.L., Karlsson, J. (2007). Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35:1333–1340.
   PubMed Web of Science ®Google Scholar
• Hinds, D., Stuve, L., Nilsen, G., Halperin, E., Eskin, E., Ballinger, D.G., et al. (2005). Whole-genome patterns of common DNA variation in three human populations. Science 307:1072–1079.
   PubMed Web of Science ®Google Scholar
• Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H.P., Brockmöller, J., Johne, A., et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473–3478.
   PubMed Web of Science ®Google Scholar
• Hreiche, R., Morissette, P., Turgeon, J. (2008). Drug-induced long QT syndrome in women: review of current evidence and remaining gaps. Gend Med 5:124–135.
   PubMed Web of Science ®Google Scholar
• Hunt, C.M., Westerkam, W.R., Stave, G.M., Wilson, J.A. (1992). Hepatic cytochrome P-4503A (CYP3A). activity in the elderly. Mech Ageing Dev 64:189–199.
   PubMed Web of Science ®Google Scholar
• Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y.Q., Klein, K., Nuessler, A.C., Neuhaus, P., Klattig, J., Eiselt, R., Koch, I., Zibat, A., Brochmöler, J., Halpert, J.R., Zanger, U.M., Wojnowshi, L. (2001). The genetic determinants of the CYP3A5 polymorphism. Pharmacogenitics. 11:773–9.
   PubMedGoogle Scholar
• Ieiri, I., Takane, H., Hirota, T., Otsubo, K., Higuchi, S... (2006). Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Exp Opin Drug Metab Toxicol 2:651–674.
   PubMed Web of Science ®Google Scholar
• Ishiguro, N., Nozawa, T., Tsujihata, A., Saito, A., Kishimoto, W., Yokoyama, K., et al. (2004). Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier. Drug Metab Dispos 32:519–524.
   PubMed Web of Science ®Google Scholar
• Jaffe, C.A., Turgeon, D.K., Lown, K., Demott-Friberg, R., Watkins, P.B. (2002). Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. Am J Physiol Endocrinol Metab 283:1008–1015.
   PubMed Web of Science ®Google Scholar
• Johne, A., Köpke, K., Gerloff, T., Mai, I., Rietbrock, S., Meisel, C., et al. (2002). Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72:584–594.
   PubMed Web of Science ®Google Scholar
• Kahan, B.D., Kramer, W.G., Wideman, C., Flechner, S.M., Lorber, M.I., Van Buren, CT. (1986). Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 41:459–464.
   PubMed Web of Science ®Google Scholar
• Kane, G.C., Lipsky, J.J. (2000). Drug-grapefruit juice interactions. Mayo Clin Proc 75:933–942.
   PubMed Web of Science ®Google Scholar
• Keshava, C., McCanlies, E.C., Weston, A. (2004). CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol 160:825–841.
   PubMed Web of Science ®Google Scholar
• Kharasch, E.D., Mautz, D., Senn, T., Lentz, G., Cox, K. (1999). Menstrual cycle variability in midazolam pharmacokinetics. J Clin Pharmacol 39:275–280.
   PubMed Web of Science ®Google Scholar
• Kharasch, E.D., Russell, M., Garton, K., Lentz, G., Bowdle, T.A., Cox, K. (1997). Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 87:26–35.
   PubMed Web of Science ®Google Scholar
• Kim, R. (2000). Transporters in drug disposition. Curr Opin Drug Discov Devel 3:94–101.
   PubMedGoogle Scholar
• Kim, R., Kim, W.Y., Benet, L.Z. (2004). P-glycoprotein (P-gp/MDR1).-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res 21:1284–1293.
   PubMed Web of Science ®Google Scholar
• Kim, R.B., Leake, B.F., Choo, E.F., Dresser, G.K., Kubba, S.V., Schwarz, U.I., et al. (2001). Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199.
   PubMed Web of Science ®Google Scholar
• Koch, I., Weil, R., Wolbold, R., Brockmöller, J., Hustert, E., Burk, O., et al. (2002). Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos 30:1108–1114.
   PubMed Web of Science ®Google Scholar
• Krecic-Shepard, M.E., Park, K., Barnas, C., Slimko, J., Kerwin, D.R., Schwartz, J.B. (2000). Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 68:130–142.
   PubMed Web of Science ®Google Scholar
• Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391.
   PubMed Web of Science ®Google Scholar
• Labbé, L., Sirois, C., Pilote, S., Arseneault, M., Robitaille, N.M., Turgeon, J., et al. (2000). Effect of gender, sex hormones, time variables, and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10:425–438.
   PubMedGoogle Scholar
• Lamba, J.K., Lin, Y.S., Schuetz, E.G., Thummel, K.E. (2002a). Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271–1294.
   PubMed Web of Science ®Google Scholar
• Lamba, J.K., Lin, Y.S., Thummel, K., Daly, A., Watkins, P.B., Strom, S., et al. (2002b). Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121–132.
   PubMedGoogle Scholar
• Lasseter, K.C., Dilzer, S.C., Vargas, R., Waldman, S., Noveck, R.J. (2004). Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study. Clin Pharmacokinet 43:121–129.
   PubMed Web of Science ®Google Scholar
• Lovern, M., Sargentini-Maier, M-L., Otoul, C., Watelet, J-B. (2009) Population Pharmacokinetic and Pharmacodynamic analysis in allergic diseases. Drug Metabolism Reviews (41).
   PubMed Web of Science ®Google Scholar
• Luner, P.E., Babu, S.R., Radebaugh, G.W. (1994). The effects of bile salts and lipids on the physicochemical behavior of gemfibrozil. Pharm Res 11:1755–1760.
   PubMed Web of Science ®Google Scholar
• Mahar Doan, K.M., Wring, S.A., Shampine, L.J., Jordan, K.H., Bishop, J.P., Kratz, J., et al. (2004). Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux, and plasma protein binding. Pharmacology 72:92–98.
   PubMed Web of Science ®Google Scholar
• Mahar Doan, K.M., Humphreys, J.E., Webster, L.O., Wring, S.A., Shampine, L.J., Serabjit-Singh, C.J., et al. (2002). Passive permeability and P-glycoprotein–mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029–1037.
   PubMed Web of Science ®Google Scholar
• Makkar, R.R., Fromm, B.S., Steinman, R.T., Meissner, M.D., Lehmann, M.H. (1993). Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270:2590–2597.
   PubMed Web of Science ®Google Scholar
• Matzke, G.R., Halstenson, C.E., Opsahl, J.A., Hilbert, J., Perentesis, G., Radwanski, E., et al. (1990). Pharmacokinetics of loratadine in patients with renal insufficiency. J Clin Pharmacol 30:364–371.
   PubMed Web of Science ®Google Scholar
• McCune, J.S., Lindley, C., Decker, J.L., Williamson, K.M., Meadowcroft, A.M., Graff, D., et al. (2001). Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol 41:723–731.
   PubMed Web of Science ®Google Scholar
• Meibohm, B., Beierle, I., Derendorf, H. (2002). How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41:329–342.
   PubMed Web of Science ®Google Scholar
• Mentré, F., Dubruc, C., Thénot, J.P. (2001). Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. J Pharmacokinet Biopharm 28:299–319.
   Google Scholar
• Mesnil, F., Mentré, F., Dubruc, C., Thénot, J.P., Mallet, A. (1998). Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the Nonparametric maximum likelihood method. J. Pharmacokinet Biopharm 26:133–161.
   PubMedGoogle Scholar
• Min, D., Ellingrod, V. (2002). C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 24:400–404.
   PubMed Web of Science ®Google Scholar
• Molimard, M., Diquet, B., Benedetti, M.S. (2004). Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine, and mizolastine in humans. Fundam Clin Pharmacol 18:399–411.
   PubMed Web of Science ®Google Scholar
• Nettles, R.E., Kieffer, T.L., Parsons, T., Johnson, J., Cofrancesco, J., Jr, Gallant, J.E., et al. (2006). Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 42:1189–1196.
   PubMed Web of Science ®Google Scholar
• Niemi, M., Kivistö, K., Hofmann, U., Schwab, M., Eichelbaum, M., Fromm, M. (2005) Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59:602–604.
   PubMed Web of Science ®Google Scholar
• Nomeir, A.A., Mojaverian, P., Kosoglou, T., Affrime, M.B., Nezamis, J., Rodwanski, E., et al. (1996). Influence of food on the oral bioavailability of loratadine and pseudoephedrine from extended-release tablets in healthy volunteers. J Clin Pharmacol 36:923–930.
   PubMed Web of Science ®Google Scholar
• Obradovic, T., Dobson, G.G., Shingaki, T., Kungu, T., Hidalgo, I.J. (2007). Assessment of the first- and second-generation antihistamines brain penetration and role of P-glycoprotein. Pharm Res 24:318–327.
   PubMed Web of Science ®Google Scholar
• Ohashi, R., Kamikozawa, Y., Sugiura, M., Fukuda, H., Yabuuchi, H., Tamai, I. (2006). Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab Dispos 34:793–799.
   PubMed Web of Science ®Google Scholar
• Oryszczyn, M.P., Bouzigon, E., Maccario, J., Siroux, V., Nadif, R., Wright, A., et al. (2007). Interrelationships of quantitative asthma-related phenotypes in the Epidemiological Study on the Genetics and Environment of Asthma, Bronchial Hyperresponsiveness, and Atopy. J Allergy Clin Immunol 119:57–63.
   PubMed Web of Science ®Google Scholar
• Paine, M.F., Ludington, S.S., Chen, M.L., Stewart, P.W., Huang, S.M., Watkins, P.B. (2005). Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos 33:426–433.
   PubMed Web of Science ®Google Scholar
• Pang, K.S. (2003). Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos 31:1507–1519.
   PubMed Web of Science ®Google Scholar
• Parkinson, A., Mudra, D.R., Johnson, C., Dwyer, A., Carroll, K.M. (2004). The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193–209.
   PubMed Web of Science ®Google Scholar
• Passalacqua, G., Canonica, G.W. (2005). A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis Clin Ther 27:979–992.
   PubMed Web of Science ®Google Scholar
• Pentikis, H.S., Huang, M.Y., Dorr, M.B., Heald, D.L. (1997). The effect of food on the bioavailability of ebastine. Am J Ther 4:80–84.
   PubMedGoogle Scholar
• Pleym, H., Spigset, O., Kharasch, E.D., Dale, O. (2003). Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand 47:241–259.
   PubMed Web of Science ®Google Scholar
• Pollock, B.G. (1997). Gender differences in psychotropic drug metabolism. Psychopharmacol Bull 33:235–241.
   PubMed Web of Science ®Google Scholar
• Prenner, B., Kim, K., Gupta, S., Khalilieh, S., Kantesaria, B., Manitpisitkul, P., et al. (2006). Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety. Exp Opin Drug Saf 5:211–223.
   PubMed Web of Science ®Google Scholar
• Ragette, R., Kamler, M., Weinreich, G., Teschler, H., Jakob, H. (2005). Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring. J Heart Lung Transpl 24:1315–1319.
   PubMed Web of Science ®Google Scholar
• Ramanathan, R., Reyderman, L., Su, A.D., Alvarez, N., Chowdhury, S.K., Alton, K.B., et al. (2007). Disposition of desloratadine in healthy volunteers. Xenobiotica 37:770–787.
   PubMed Web of Science ®Google Scholar
• Renwick, A.G. (1999). The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy 29(Suppl 3):116–124.
   PubMedGoogle Scholar
• Sakaeda, T., Nakamura, T., Horinouchi, M., Kakumoto, M., Ohmoto, N., Sakai, T., et al. (2001). MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18:1400–1404.
   PubMed Web of Science ®Google Scholar
• Salokangas, R.K., Saarijarvi, S., Taiminen, T., Lehto, H., Niemi, H., Ahola, V., et al. (1997). Effect of smoking on neuroleptics in schizophrenia. Schizophr Res 23: 55–60.
   PubMed Web of Science ®Google Scholar
• Sarashina, A., Tatami, S., Yamamura, N., Tsuda, Y., Igarashi, T. (2005). Population pharmacokinetics of epinastine, a histamine H1-receptor antagonist, in adults and children. Br J Clin Pharmacol 59:43–53.
   PubMed Web of Science ®Google Scholar
• Saruwatari, J., Matsunaga, M., Ikeda, K., Nakao, M., Oniki, K., Seo, T., et al. (2006). Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia. Eur J Clin Pharmacol 62:995–1001.
   PubMed Web of Science ®Google Scholar
• Sata, F., Sapone, A., Elizondo, G., Stocker, P., Miller, V.P., Zheng, W., et al. (2000). CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48–56
   PubMed Web of Science ®Google Scholar
• Schmucker, D.L., Woodhouse, K.W., Wang, R.K., Wynne, H., James, O.F., McManus, M., et al. (1990). Effects of age and gender on in vitro properties of human liver microsomal monooxygenases Clin Pharmacol Ther 48:365–374.
   PubMed Web of Science ®Google Scholar
• Schran, H.F., Petryk, L., Chang, C.T., O’Connor, R., Gelbert, M.B. (1996). The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J Clin Pharmacol 36:911–922.
   PubMed Web of Science ®Google Scholar
• Schuetz, E.G., Furuya, K.N., Schuetz, J.D. (1995). Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275:1011–1018.
   PubMed Web of Science ®Google Scholar
• Schwab, M., Eichelbaum, M., Fromm, M. (2003). Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43:285–307.
   PubMed Web of Science ®Google Scholar
• Schwartz, J.B. (2003). The influence of sex on pharmacokinetics. Clin Pharmacokinet 42:107–121.
   PubMed Web of Science ®Google Scholar
• Sharma, A., Hamelin, B.A. (2003). Classic Histamine H1 Receptor Antagonists: A Critical Review of their Metabolic and Pharmacokinetic Fate from a Bird’s Eye View. Current Drug Metabolism. 4:105–129.
   PubMed Web of Science ®Google Scholar
• Shon, J., Chun, H., Kim, K., Kim, E., Yoon, Y., Jang, I., et al. (2002). The PK and PD of fexofenadine in relation to MDR1 genetic polymorphism in Korean healthy subjects. Clin Pharmacol Ther 71:P71. [poster abstract]
   Web of Science ®Google Scholar
• Siegsmund, M., Brinkmann, U., Scháffeler, E., Weirich, G., Schwab, M., Eichelbaum, M., et al. (2002). Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 13:1847–1854.
   PubMed Web of Science ®Google Scholar
• Sim, S.C., Edwards, R.J., Boobis, A.R., Ingelman-Sundberg, M. (2005). CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet Genomics 15:625–631.
   PubMed Web of Science ®Google Scholar
• Solans, A., Carbó, M.L., Peña, J., Nadal, T., Izquierdo, I., Merlos, M. (2007). Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. Clin Ther 29:900–908.
   PubMed Web of Science ®Google Scholar
• Spina, S.P., Ensom, M.H. (2007). Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy 27:389–398.
   PubMed Web of Science ®Google Scholar
• Stoltz, M., Arumugham, T., Lippert, C., Yu, D., Bhargava, V., Eller, M., et al. (1997). Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A). Biopharm Drug Dispos 18:645–648.
   PubMed Web of Science ®Google Scholar
• Suzuki, T., Zhao, Y.L., Nadai, M., Naruhashi, K., Shimizu, A., Takagi, K., et al. (2006). Gender-related differences in expression and function of hepatic P-glycoprotein and multidrug resistance-associated protein (Mrp2) in rats. Life Sci 79:455–461.
   PubMed Web of Science ®Google Scholar
• Tanabe, M., Ieiri, I., Nagata, N., Inoue, K., Ito, S., Kanamori, Y., et al. (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–1143.
   PubMed Web of Science ®Google Scholar
• Tanaka, Y., Fujiwara, T., Esumi, Y. (1992). Sex difference in the excretion of zenarestat in mice, rats, dogs, and humans. Xenobiotica 22:941–947.
   PubMed Web of Science ®Google Scholar
• Tang, K., Ngoi, S., Gwee, P., Chua, J., Lee, E., Chong, S., et al. (2002). Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12:437–450.
   PubMedGoogle Scholar
• Timmer, C.J., Sitsen, J.M., Delbressine, L.P. (2000). Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 38:461–474.
   PubMed Web of Science ®Google Scholar
• Undevia, S.D., Gomez-Abuin, G., Ratain, M.J. (2005). Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 5:447–458.
   PubMed Web of Science ®Google Scholar
• Vacher, V., Wu, C., Benet, L. (1995). Overlapping substrate specificity and tissue distribution of cytochrome P4503A4 and P-glycoprotein: implication for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129–134.
   PubMed Web of Science ®Google Scholar
• Vermeeren, A., Ramaekers, J.G., O’Hanlon, J.F. (2002). Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol 16:57–64.
   PubMed Web of Science ®Google Scholar
• Verster, J.C., Volkerts, E.R. (2004). Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 92:294–303.
   PubMed Web of Science ®Google Scholar
• von Ahsen, N., Richter, M., Grupp, C., Ringe, B., Oellerich, M., Armstrong, V.W. (2001). No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 47:1048–1052.
   PubMed Web of Science ®Google Scholar
• Watkins, P. (1997). The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161–170.
   PubMed Web of Science ®Google Scholar
• White, H.D., Barbash, G.I., Modan, M., Simes, J., Diaz, R., Hampton, J.R., et al. (1993). After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. Circulation 88:2097–2103.
   PubMed Web of Science ®Google Scholar
• Whitfield, P.F., Hobsley, M. (1987). Comparison of maximal gastric secretion in smokers and nonsmokers with and without duodenal ulcer. Gut 28:557–560.
   PubMed Web of Science ®Google Scholar
• Wojnowski, L., Kamdem, L.K. (2006). Clinical implications of CYP3A polymorphisms. Exp Opin Drug Metab Toxicol 2:171–182.
   PubMed Web of Science ®Google Scholar
• Wolbold, R., Klein, K., Burk, O., Nüssler, A.K., Neuhaus, P., Eichelbaum, M., et al. (2003). Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978–988.
   PubMed Web of Science ®Google Scholar
• Wong, L.T., Sitar, D.S., Aoki, F.Y. (1995). Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. Br J Clin Pharmacol 39:81–84.
   PubMed Web of Science ®Google Scholar
• Yates, C., Zhang, W., Song, P., Li, S., Gaber, A., Kotb, M., et al. (2003). The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 43:555–564.
   PubMed Web of Science ®Google Scholar
• Yi, S.Y., Hong, K.S., Lim, H.S., Chung, J.Y., Oh, D.S., Kim, J.R., Jung, H.R., Cho, J.Y., Yu, K.S., Jang, I.J., Shin, S.G. (2004). A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther. 76:418–27.
   PubMed Web of Science ®Google Scholar
• Yin, O.Q., Shi, X.J., Tomlinson, B., Chow, M.S. (2005). Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. Drug Metab Dispos 33:1283–1287.
   PubMed Web of Science ®Google Scholar
• Zevin, S., Benowitz, N.L. (1999). Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 36:425–438.
   PubMed Web of Science ®Google Scholar
• Zhang, J., Kuehl, P., Green, E., Touchman, J., Watkins, P., Daly, A., et al. (2001). The human pregnane X receptor: genomic structure and identification and functional characterization of of natural allelic variants. Pharmacogenetics 11:555–572.
   PubMedGoogle Scholar